Future prospects for hormone replacement therapy

British Medical Bulletin

Volumn 48, Issue 2, 1992, Pages 458-468

  Reeve, J ^a  

^a MRC Clinical Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; BREAST CANCER; ESTROGEN DEFICIENCY; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MEDICAL RESEARCH; MENOPAUSE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STROKE; UTERUS BLEEDING;

BREAST NEOPLASMS; CEREBROVASCULAR DISORDERS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FORECASTING; HUMAN; MIDDLE AGE; MYOCARDIAL INFARCTION; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 0026579492     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a072555     Document Type: Article

References (38)

1. Solomon L, Bone density in ageing Caucasian and African populations. Lancet 1979; 2: 1325-1330
2. Law MR, Wald NJ, Meade TW. Strategies for prevention of osteoporosis and hip fracture. Br Med J 1991; 303: 453-459
3. Grimley Evans J. The significance of osteoporosis. In: Smith R ed. Osteoporosis 1990. London: Royal College of Physicians, 1990: pp. 1-8
4. Wilkes HC, Meade TW. Hormone replacement therapy in general practice: a survey of doctors in the MRC’s general practice research framework. Br Med J 1991; 302: 1317-1320
5. Robine JM, Ritchie K. Healthy life expectancy: evaluation of global indicator of change in population health. Br Med J 1991; 302: 457-460
6. Todd C, Williams R, Pryor G, Parker M, Myles J. Early discharge to ‘hospital at home’ after fracture of neck of femur: psychosocial factors. In: Brenner G, Weber I, eds. Health services research and primary health care (Proceedings of 2nd European Conference). Koln: Deutsche Arzte-Verlag, 1991: pp. 185-189
7. Roche M, Vessey M. Hormone replacement therapy in the menopause: risks, benefits and costs. In: Smith R. ed. Osteoporosis 1990. London: Royal College of Physicians, 1990: pp. 189-198. (erratum)
8. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919-923
9. Ross PD, Davis JW, Vogel JM, Wasnich RD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tiss Int 1990; 46: 149-161
10. Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fracture in women. J Am Med Assoc 1990; 263: 665-668
11. Cooper C, Atkinson E, O’Fallon WM, Riggs BL, Melton LJ III. The epidemiology of vertebral fractures in Rochester, Minnesota. J Bone Min Res 1991; 6 (suppl 1): S300 (abstract)
12. Hui SL, Slemenda CW, Johnston CC Jr. The contribution of bone loss to postmenopausal osteoporosis. Osteoporosis Int 1990; 1: 30-34
13. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss. Br Med J 1991; 303: 961-964
14. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, Harris MM. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation and hormone replacement therapy. N Engl J Med 1991; 325: 1189-1195
15. Report from the Scientific Advisory Board of the National Osteoporosis Foundation. Raisz LG, ed. J Bone Min Res 1989; 4 (suppl 2): S1-28
16. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204
17. Christiansen C, Riis BJ. 17fl-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-841
18. Gallagher JC, Kable W 1, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90: 171-178
19. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109
20. Samsioe G, Mattsson LA. Effects of estrogens and progestogens on lipid metabolism. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990: pp. 1806-1816
21. Christiansen C, Christensen MS, Transbol IB. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1: 459-461
22. Lindsay R, Hart DM, Abdalla H, Al-Azzawu F. Inter-relationship of bone loss and its prevention, and fracture expression. In: Osteoporosis 1987. eds. Christiansen C, Johansen JS, Riis BJ. Copenhagen: Osteopress ApS, 1987: pp.508-512
23. Reeve J, Green JR, Hesp R et al. Determinants of axial bone loss in the early postmenopause: The Harrow post menopausal bone loss study. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990: pp.101-103
24. Reeve J. Restoring trabecular bone mass in established osteoporosis. In: Smith R, ed. Osteoporosis 1990. London: The Royal College of Physicians, 1990: pp.143-155
25. Reginster YJ, Albert A, Lecart MP et al. One year controlled randomised trial of prevention of early post-menopausal bone loss by intranasal calcitonin. Lancet 1987; 2: 1481-1483
26. Overgaard K, Riis BJ, Christiansen C et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-442
27. Guesens P, Dequeker J. Long-term effect of nandrolone decanoate, l6- hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodelling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. J Bone Min Res 1986; 1: 346-357
28. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271
29. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79
30. Gennari C. The analgesic activity of intranasal salmon calcitonin in the osteoporotic patient. New findings. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990: pp. 1872-1887
31. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809
32. Kleerekoper M, Peterson EL, Nelson DA et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991; 1: 155-161
33. Mamelle N, Meunier PJ, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361-365
34. Reeve J, Davies UM, Hesp R, McNally E, Katz D. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride. Br Med J 1990; 301: 314-318
35. Beaglehole R. Oestrogens and cardiovascular disease. Br Med J 1988; 297: 571-572
36. Draper J, Roland M. Perimenopausal women’s views on taking hormone replacement therapy to prevent osteoporosis. Br Med J 1990; 300: 786-788
37. Benz DJ, Haussler MR, Komm BS. Estrogen binding and estrogenic responses in normal human osteoblast-like cells. J Bone Min Res 1991; 6: 531-541
38. Spector TD, Cooper C, Fenton Lewis A. Trends in admission for hip fracture in England and Wales 1968-85. Br Med J 1990; 300: 1173-1174